PRKCB and B-cell chronic lymphocytic leukemia: While there are no reports of clinical trials of enzastaurin in CLL, an on-going phase I trial of MS-553 (NCT03492125), will determine whether the drug is tolerable and whether inhibition of PKC-b may represent another therapeutic strategy for refractory CLL.